{'52WeekChange': 1.8022599,
 'SandP52WeekChange': 0.0644362,
 'address1': '701 Veterans Circle',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.15,
 'askSize': 1300,
 'averageDailyVolume10Day': 45949850,
 'averageVolume': 6926400,
 'averageVolume10days': 45949850,
 'beta': 2.823529,
 'beta3Year': None,
 'bid': 5.15,
 'bidSize': 2200,
 'bookValue': -0.972,
 'category': None,
 'circulatingSupply': None,
 'city': 'Warminster',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 9.02,
 'dayLow': 4.77,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.437,
 'enterpriseToRevenue': 58.73,
 'enterpriseValue': 400715520,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '267 282 0411',
 'fiftyDayAverage': 2.2134285,
 'fiftyTwoWeekHigh': 9.02,
 'fiftyTwoWeekLow': 0.82,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 38348742,
 'forwardEps': -0.85,
 'forwardPE': -5.835294,
 'fromCurrency': None,
 'fullTimeEmployees': 78,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.30162,
 'heldPercentInstitutions': 0.35036,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1288828800,
 'lastSplitFactor': '1:5',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/arbutusbio.com',
 'longBusinessSummary': 'Arbutus Biopharma Corporation, a biopharmaceutical '
                        'company, engages in the discovery, development, and '
                        'commercialization of a cure for patients suffering '
                        'from chronic Hepatitis B virus (HBV) infection in the '
                        'United States. Its HBV product pipeline consists of '
                        'AB-836, a capsid inhibitor that has the potential to '
                        'inhibit HBV replication by preventing the assembly of '
                        'functional viral capsids; and AB-423, which is in '
                        'pre-clinical studies. The company also develops RNAi '
                        'drugs, which utilize the RNA interference pathway, '
                        'allows for a novel approach to treating disease. Its '
                        'RNAi HBV candidates are designed to reduce hepatitis '
                        'B surface antigen expression in patients chronically '
                        'infected with HBV. In addition, it develops AB-729, a '
                        'second generation RNAi therapeutic targeted to '
                        'hepatocytes; HBV RNA destabilizer, an orally active '
                        'agent that cause the destabilization of HBV RNAs, '
                        'which leads to RNA degradation and to reduction in '
                        'HBsAg levels. Further, the company engages conducting '
                        'a Phase 1a/1b clinical trial and several pre-clinical '
                        'and investigational new drug-enabling studies to '
                        'evaluate proprietary HBV therapeutic agents, together '
                        'with standard of care therapies, and in combination '
                        'with each other. It has strategic alliance, '
                        'licensing, and research collaboration agreements with '
                        'Marqibo; Gritstone Oncology, Inc.; and Acuitas '
                        'Therapeutics, Inc. The company was formerly known as '
                        'Tekmira Pharmaceuticals Corporation and changed its '
                        'name to Arbutus Biopharma Corporation in July 2015. '
                        'Arbutus Biopharma Corporation is headquartered in '
                        'Warminster, Pennsylvania.',
 'longName': 'Arbutus Biopharma Corporation',
 'market': 'us_market',
 'marketCap': 342048544,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_34160168',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -155744992,
 'nextFiscalYearEnd': 1640908800,
 'open': 7.98,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '267 469 0914',
 'previousClose': 6.2,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 50.131695,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 9.02,
 'regularMarketDayLow': 4.77,
 'regularMarketOpen': 7.98,
 'regularMarketPreviousClose': 6.2,
 'regularMarketPrice': 7.98,
 'regularMarketVolume': 217803150,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 68961400,
 'sharesPercentSharesOut': 0.0093,
 'sharesShort': 641197,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 565276,
 'shortName': 'Arbutus Biopharma Corporation',
 'shortPercentOfFloat': 0.0125,
 'shortRatio': 0.57,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'ABUS',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.592,
 'twoHundredDayAverage': 2.1889207,
 'volume': 217803150,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.arbutusbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '18974'}